Stroke thrombolysis in the elderly: Risk or benefit?

Neurology

Volumn 65, Issue 11, 2005, Pages 1690-1691

  Hemphill III, J Claude ^a,c   Lyden, Patrick ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FIBRINOLYTIC THERAPY; HIGH RISK POPULATION; HUMAN; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEX RATIO; STROKE; TREATMENT OUTCOME; AGE; AGED; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG CONTRAINDICATION; ETHICS; FEMALE; MALE; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT WITHDRAWAL;

AGE FACTORS; AGED; AGING; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33645061545     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000192631.39824.93     Document Type: Editorial

References (10)

1. Kammersgaard LP, Jorgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004;33:149-154.
2. Ridker PM, Hennekens CH. Age and thrombolytic therapy. Circulation 1996;94:1807-1808.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
4. Ford GA. Thrombolysis for stroke in the over 80s. Age Ageing 2004;33:95-97.
5. Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795-1798.
6. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000;31:370-375.
7. Simon JE, Sandler DL, Pexman JH, Hill MD, Buchan AM. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? The Calgary experience. Age Ageing 2004;33:143-149.
8. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-1838.
9. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-2125.
10. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-2118.